Key result
Ventricular tachycardia ablation using a novel lattice-tip catheter toggling between pulsed field and radiofrequency energy was feasible and safe in 4 patients, with no recurrences at 5 months.
Why the study?
Pre-clinical studies of a novel lattice-tip catheter toggling between pulsed field and radiofrequency energy showed promising results for ventricular tissue, but clinical studies for ventricular tachycardia ablation were lacking.
Is mapping and ablation of ventricular tachycardia using a novel dual-energy lattice-tip catheter toggling between pulsed field and radiofrequency energy feasible and safe in patients with ventricular arrhythmias?
Case Report (n=4)
Is mapping and ablation of ventricular tachycardia using a novel dual-energy lattice-tip catheter toggling between pulsed field and radiofrequency energy feasible and safe in patients with ventricular arrhythmias?
This first-in-human case series demonstrates that ventricular tachycardia mapping and ablation using a dual-energy (pulsed field and radiofrequency) lattice-tip catheter is clinically feasible and safe, achieving no recurrences at 5 months in four patients.
Answers are grounded in this paper and cite their sources.
First-in-human VT ablation experience with lattice-tip PF/RF catheter; hypothesis-generating and leaves open comparative efficacy versus standard tools.
The novel mapping and ablation lattice-tip catheter (Sphere-9; Medtronic, Minneapolis, MN, USA)1,2 can toggle between pulsed field (PF)3 and radiofrequency (RF) energy. In pre-clinical studies, it showed promising results for ventricular tissue treatment.4,5 However, there are no clinical studies reported for ventricular tachycardia (VT) ablation.6 All consecutive patients undergoing VT ablation with the lattice-tip catheter and Affera mapping system (Affera Mapping System; Medtronic) were prospectively included. Patients were selected after a failed ablation (Patients 1, 2, and 4) assuming higher penetrance in scarred tissue with the large footprint catheter and based on limited catheter availability. In the absence of regulatory approval of the device for the treatment of ventricular arrhythmias, all patients were informed about the exploratory character of the device and signed an informed consent for the procedure, and institutional compassionate use exemption was applied. The study complied with the Declaration of Helsinki as revised in 2013. The ethics committee approved the study. All procedures were performed in general anaesthesia and under muscle relaxants. An anterograde trans-septal approach was used in all patients. Substrate activation and voltage mapping were performed in all patients in sinus rhythm.7 Scar was defined as bipolar voltage < 0.5 mV and abnormal voltage as <1 mV, with adjustment of voltage cut-offs when required. Ventricular tachycardia activation mapping was performed if tolerated. Ablation was performed with PF or RF at the operators’s discretion [PF-first approach in the right ventricle (RV) and RF-first approach in the left ventricle (LV)]: (i) a ventricular PF pulse was used with the following characteristics: 1500 pulses/train, 12 trains/application, and 350 ms inter-train delay; and (ii) ventricular RF application was performed in temperature control mode with target temperature of 60° and 40% current limit with 30- or 60-s duration. Substrate and VT ablation were performed, based on clinical indication and operator preference, aiming at non-inducibility of any VT. A total of four patients were included. The mean age was 55.8 ± 18.8 years, and all patients were males. The mean LV ejection fraction was 45.0 ± 17.8%. Three patients had an implantable cardioverter defibrillator (ICD) in place and, Patient 2 received the ICD after the ablation. Three patients received appropriate shocks prior to the procedure, and Patient 3 had spontaneous haemodynamically unstable fast VT. Patients 1, 2, and 4 underwent previous ablation procedures (Table 1). Patient characteristics ARVC, arrhythmogenic right ventricular cardiomyopathy; BMI, body mass index; ICM, ischaemic cardiomyopathy; LVEF, left ventricular ejection fraction; NIDCM, non-ischaemic dilated cardiomyopathy; OSAS, obstructive sleep apnoea syndrome. Patient characteristics ARVC, arrhythmogenic right ventricular cardiomyopathy; BMI, body mass index; ICM, ischaemic cardiomyopathy; LVEF, left ventricular ejection fraction; NIDCM, non-ischaemic dilated cardiomyopathy; OSAS, obstructive sleep apnoea syndrome. Mean procedure time was 201 ± 73.6 min. In three patients, PF applications were performed with a mean of 45 ± 29.6 applications and a PF time of 92.2 ± 122.0 s. None of the pulsed-field ablation (PFA) applications induced VT/ventricular fibrillation (VF). Irritative firing >3 s post-ablation was noticed in 4 of the 135 applications (all in Patient 1). In three patients, RF applications were performed with a mean of 15.0 ± 23.3 applications and RF time of 4.8 ± 7.8 min. In Patients 3 and 4, first RF and then PFA applications were performed. The mean dense scar area (<0.5 mV) increased from 7.5 ± 5.5 cm2 to 20.3 ± 12 cm2 and the low voltage zone (<1 mV) area from 10.4 ± 4.6 cm2 to 27.5 ± 11.5 cm2 post-ablation. Patient 1 had Brugada syndrome and repetitive ICD shocks with a previous failed thoracoscopic RV outflow tract (RVOT) ablation secondary to an abnormal amount of epicardial fat around the anterior RVOT. The patient had subsequent recurrent VF treated with ICD shocks and frequent premature ventricular contractions (PVCs) with a burden of >20%. Only non-sustained ventricular tachycardia (NSVT) was induced, and three different spontaneous PVCs were documented (two PVCs had left bundle branch block morphology, superior axis, and R wave transition V5 and V6, and one PVC had left bundle branch block morphology, inferior axis, and R wave transition V4). Pulsed field ablation in the endocardial RVOT and PF and RF ablations in the anterolateral peri-tricuspid low voltage zones were performed based on sinus rhythm activation and pace mapping and PVC activation and pace mapping. The endpoint of the procedure was PVC and NSVT suppression, local non-capture with high output pacing and absence of late activation inside the ablated region (Figure 1). Ventricular tachycardia ablation with lattice dual energy catheter. A–D refer to Patient 1. E–G refer to Patient 4. EGM, electrogram; LL, left lateral; LVOT, left ventricular outflow tract; RVOT, right ventricular outflow tract; VT, ventricular tachycardia. Patient 2 had arrhythmogenic cardiomyopathy, spontaneous fast VT, and PVCs. Multiple VTs were induced from the RV peri-tricuspid basal-mid infero-lateral scar. Sinus rhythm voltage and activation and tolerated VTs activation, entrainment, and reversible pulse mapping were performed. In all mapped VTs simultaneous large area endocardial activation maximum 5 mc before the beginning of QRS complex and with entrainment long post-pacing interval at the earliest sites were observed, suggesting epicardial circuits. Pulsed field ablation was performed with the combined endpoints of PVC suppression, local non-capture with high output pacing, and absence of late activation inside the ablated region. Patient 3 with ischaemic cardiomyopathy and appropriate ICD therapy had no inducible VT. Substrate mapping in sinus rhythm showed LV septal and inferior and lateral mid-basal scar. Substrate RF ablation and PF ablation were performed. The endpoint was local non-capture with the absence of late activation inside the ablated region. Patient 4 with non-ischaemic cardiomyopathy, previous LV outflow tract (LVOT) endocardial ablation, and VT recurrence had inducible multiple (3) morphology VTs. Substrate mapping showed a basal septal, peri-aortic LVOT, and lateral basal scar. Radiofrequency applications at the earliest site of activation mapping during all of the mapped VTs terminated the VT (Figure 1). The endpoint was local non-capture with the absence of late activation inside in the ablated region and non-inducibility of the initial VTs. No procedural complications were observed acutely or in the follow-up. Post-operative echocardiogram did not show new ventricular dysfunction. There were no signs of haemolysis. At a median follow-up of 5 months, no recurrences were observed. PFA was used first in the first two patients because only a RV ablation was performed, based on extrapolation from pre-clinical studies. It was assumed that ventricular PF pulse may reach a depth that is compatible with a transmural lesion in the RV also in the presence of scar.4 In the LV, we used an RF-first approach because lesion depth was felt to be better titratable and peri-ablation local electrogram signal analysis easier interpretable with RF applications.8 Also, a possible stunning effect of PFA on large portion of the LV in patients with an already decreased systolic function was considered. This could have theoretically caused acute haemodynamic deterioration during the procedure. Herein, we describe the first experience of VT ablation with the lattice-tip catheter. In conclusion, substrate, activation, entrainment mapping, and PF and RF ablation with the lattice-tip catheter in a clinical setting were feasible and safe with reasonable acute results. Further studies are needed to clarify the optimal ablation endpoints and confirm our findings. None declared. The data underlying this article will be shared on reasonable request to the corresponding author.
No takes yet. Share an insight, caveat, or question.
Pannone et al. (2024) conducted a case report in Ventricular tachycardia (n=4). Lattice-tip catheter (Sphere-9) toggling between pulsed field and radiofrequency energy was evaluated on Feasibility, safety, and acute results (non-inducibility of VT, PVC suppression). Ventricular tachycardia ablation using a novel lattice-tip catheter toggling between pulsed field and radiofrequency energy was feasible and safe in 4 patients, with no recurrences at 5 months.
Synapse has enriched 10 related papers. Consider them for comparative context: